In The News Posted July 2, 2019 Share Posted July 2, 2019 OTTAWA, Ontario, July 2, 2019 /PRNewswire/ -- Orion Biotechnology Canada Ltd., today announced the publication of preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in a murine model of multiple sclerosis in Science Translation Medicine [1]. Viral infection early in life is... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.